Written by: Martina Fraga, PharmD
This purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.
Continue reading Ovarian Cancer: PARP Inhibitor Eligibility
Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health
Cyclin-dependent kinase (CDK) 4/6 inhibitors have demonstrated significant advances in the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor (HER2) negative advanced breast cancer. While current available data do not support the preferential use of one agent over the other, the dosing and safety monitoring differ and may help in treatment decision making with patients. Multi-disciplinary care teams have key roles in education and supportive care management to optimize the use of these agents and disease response1,2. Continue reading CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer